---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-042266"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2024-10-04T23:59:59+00:00"
generated_at: "2026-05-30T20:21:12.195442+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bioventus divests Advanced Rehabilitation business to Accelmed for up to $45M

## Summary
- Total cash consideration of $45M: $25M at close plus up to $20M in earn-outs.
- Net proceeds of ~$20M after fees and expenses will be used to repay existing debt.
- Divestiture reduces annual revenue by ~$50M and annual Adj. EBITDA by ~$6M.
- Transaction expected to close in Q4 2024, subject to customary conditions.
- Bioventus to focus on core business and improve liquidity with the sale.

## SEC filing metadata
- accession: 0001628280-24-042266
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2024-10-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828024042266/0001628280-24-042266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828024042266/bvs-20240930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-042266
- JSON: https://secwatch.observer/filing/0001628280-24-042266.json
- Plain text: https://secwatch.observer/filing/0001628280-24-042266.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.